JPH05508159A - 酸化リポプロテインを使用するウイルス感染症の治療方法 - Google Patents

酸化リポプロテインを使用するウイルス感染症の治療方法

Info

Publication number: JPH05508159A
Authority: JP; Japan
Prior art keywords: lipoprotein; blood; treatment method; oxidized; lipoproteins
Prior art date: 1990-07-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP91513333A

Other languages

English (en)

Japanese (ja)

Inventor

フォッセル，エリック　ティー．

リディー，ジェームズ　イー．

Original Assignee

ザ　ベス　イスラエル　ホスピタル　アソシエイション

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-07-18

Filing date

1991-07-11

Publication date

1993-11-18

1991-07-11 Application filed by ザ　ベス　イスラエル　ホスピタル　アソシエイション filed Critical ザ　ベス　イスラエル　ホスピタル　アソシエイション

1993-11-18 Publication of JPH05508159A publication Critical patent/JPH05508159A/ja

Status Pending legal-status Critical Current

Links

108090001030 Lipoproteins Proteins 0.000 title claims description 139
102000004895 Lipoproteins Human genes 0.000 title claims description 139
208000036142 Viral infection Diseases 0.000 title claims description 27
230000009385 viral infection Effects 0.000 title claims description 27
238000000034 method Methods 0.000 claims description 89
210000004369 blood Anatomy 0.000 claims description 78
239000008280 blood Substances 0.000 claims description 78
208000030507 AIDS Diseases 0.000 claims description 20
230000001590 oxidative effect Effects 0.000 claims description 18
239000007800 oxidant agent Substances 0.000 claims description 17
150000002978 peroxides Chemical class 0.000 claims description 17
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 14
150000003904 phospholipids Chemical class 0.000 claims description 14
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 13
150000002632 lipids Chemical class 0.000 claims description 13
239000001301 oxygen Substances 0.000 claims description 13
229910052760 oxygen Inorganic materials 0.000 claims description 13
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 11
150000001451 organic peroxides Chemical class 0.000 claims description 10
230000003647 oxidation Effects 0.000 claims description 10
238000007254 oxidation reaction Methods 0.000 claims description 10
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 9
238000005502 peroxidation Methods 0.000 claims description 9
TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims description 9
150000003626 triacylglycerols Chemical class 0.000 claims description 9
238000010521 absorption reaction Methods 0.000 claims description 8
201000010099 disease Diseases 0.000 claims description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
208000024891 symptom Diseases 0.000 claims description 8
PAOHAQSLJSMLAT-UHFFFAOYSA-N 1-butylperoxybutane Chemical group CCCCOOCCCC PAOHAQSLJSMLAT-UHFFFAOYSA-N 0.000 claims description 7
238000005481 NMR spectroscopy Methods 0.000 claims description 7
150000001840 cholesterol esters Chemical class 0.000 claims description 7
239000007788 liquid Substances 0.000 claims description 7
OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 claims description 6
102000004190 Enzymes Human genes 0.000 claims description 6
108090000790 Enzymes Proteins 0.000 claims description 6
108010001336 Horseradish Peroxidase Proteins 0.000 claims description 6
230000036770 blood supply Effects 0.000 claims description 6
239000000126 substance Substances 0.000 claims description 6
238000004458 analytical method Methods 0.000 claims description 5
235000019192 riboflavin Nutrition 0.000 claims description 5
239000002151 riboflavin Substances 0.000 claims description 5
AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 4
102000004316 Oxidoreductases Human genes 0.000 claims description 4
108090000854 Oxidoreductases Proteins 0.000 claims description 4
229960002477 riboflavin Drugs 0.000 claims description 4
102000003820 Lipoxygenases Human genes 0.000 claims description 3
108090000128 Lipoxygenases Proteins 0.000 claims description 3
102000003992 Peroxidases Human genes 0.000 claims description 3
108040007629 peroxidase activity proteins Proteins 0.000 claims description 3
238000002560 therapeutic procedure Methods 0.000 claims description 3
HVYWMOMLDIMFJA-UHFFFAOYSA-N 3-cholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 HVYWMOMLDIMFJA-UHFFFAOYSA-N 0.000 claims 3
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical class CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 3
230000006378 damage Effects 0.000 claims 3
239000000243 solution Substances 0.000 claims 3
238000001802 infusion Methods 0.000 claims 2
239000003054 catalyst Substances 0.000 claims 1
230000003197 catalytic effect Effects 0.000 claims 1
238000002347 injection Methods 0.000 claims 1
239000007924 injection Substances 0.000 claims 1
210000004027 cell Anatomy 0.000 description 50
241000700605 Viruses Species 0.000 description 20
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 16
235000018102 proteins Nutrition 0.000 description 11
102000004169 proteins and genes Human genes 0.000 description 11
108090000623 proteins and genes Proteins 0.000 description 11
241000725303 Human immunodeficiency virus Species 0.000 description 10
108010007622 LDL Lipoproteins Proteins 0.000 description 9
239000003814 drug Substances 0.000 description 7
229940079593 drug Drugs 0.000 description 7
210000000170 cell membrane Anatomy 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
231100000331 toxic Toxicity 0.000 description 5
230000002588 toxic effect Effects 0.000 description 5
108010004103 Chylomicrons Proteins 0.000 description 4
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 4
239000000427 antigen Substances 0.000 description 4
235000012000 cholesterol Nutrition 0.000 description 4
239000002245 particle Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
230000035945 sensitivity Effects 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
238000004448 titration Methods 0.000 description 4
208000031886 HIV Infections Diseases 0.000 description 3
208000037357 HIV infectious disease Diseases 0.000 description 3
241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
239000013043 chemical agent Substances 0.000 description 3
231100000433 cytotoxic Toxicity 0.000 description 3
230000001472 cytotoxic effect Effects 0.000 description 3
231100000135 cytotoxicity Toxicity 0.000 description 3
230000003013 cytotoxicity Effects 0.000 description 3
230000007717 exclusion Effects 0.000 description 3
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
230000003859 lipid peroxidation Effects 0.000 description 3
230000008569 process Effects 0.000 description 3
230000029058 respiratory gaseous exchange Effects 0.000 description 3
230000032258 transport Effects 0.000 description 3
108010004942 Chylomicron Remnants Proteins 0.000 description 2
208000035473 Communicable disease Diseases 0.000 description 2
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
239000002253 acid Substances 0.000 description 2
238000002405 diagnostic procedure Methods 0.000 description 2
238000010586 diagram Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000032050 esterification Effects 0.000 description 2
238000005886 esterification reaction Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
150000002211 flavins Chemical class 0.000 description 2
239000012530 fluid Substances 0.000 description 2
238000007429 general method Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
108010071584 oxidized low density lipoprotein Proteins 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
230000003014 reinforcing effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
241000701022 Cytomegalovirus Species 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000257303 Hymenoptera Species 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
108010093096 Immobilized Enzymes Proteins 0.000 description 1
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
102000011965 Lipoprotein Receptors Human genes 0.000 description 1
108010061306 Lipoprotein Receptors Proteins 0.000 description 1
108010047620 Phytohemagglutinins Proteins 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
244000195452 Wasabia japonica Species 0.000 description 1
235000000760 Wasabia japonica Nutrition 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 description 1
GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
230000036541 health Effects 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
235000020778 linoleic acid Nutrition 0.000 description 1
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
230000037361 pathway Effects 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
229910000498 pewter Inorganic materials 0.000 description 1
239000010957 pewter Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000001885 phytohemagglutinin Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
150000003287 riboflavins Chemical class 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
-1 sterol esters Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
ZCUFMDLYAMJYST-UHFFFAOYSA-N thorium dioxide Chemical compound O=[Th]=O ZCUFMDLYAMJYST-UHFFFAOYSA-N 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
230000035899 viability Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP91513333A 1990-07-18 1991-07-11 酸化リポプロテインを使用するウイルス感染症の治療方法 Pending JPH05508159A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US55480790A	1990-07-18	1990-07-18
US554,807		1990-07-18
PCT/US1991/004913 WO1992001467A1 (en)	1990-07-18	1991-07-11	Method for treating viral infections using oxidized lipoproteins

Publications (1)

Publication Number	Publication Date
JPH05508159A true JPH05508159A (ja)	1993-11-18

Family

ID=24214788

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP91513333A Pending JPH05508159A (ja)	1990-07-18	1991-07-11	酸化リポプロテインを使用するウイルス感染症の治療方法

Country Status (9)

Country	Link
EP (1)	EP0539506A4 (fi)
JP (1)	JPH05508159A (fi)
AU (1)	AU8305691A (fi)
CA (1)	CA2086921A1 (fi)
FI (1)	FI930123A0 (fi)
IE (1)	IE912498A1 (fi)
PT (1)	PT98373A (fi)
WO (1)	WO1992001467A1 (fi)
ZA (1)	ZA915639B (fi)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4336641C2 (de) *	1993-10-22	1995-09-07	Deutsches Rheuma Forschungszen	Verwendung von Superoxid-Dismutase (SOD) zur Behandlung retroviraler Erkrankungen
ATE406908T1 (de) *	2000-10-20	2008-09-15	Hamburger Stiftung Zur Foerder	Oxidierte proteine und deren biologische und therapeutische aktivität sowie diagnostische verwendung über die hemmung der interaktion zwischen oxidierten proteinen und cd36

1991
- 1991-07-11 CA CA002086921A patent/CA2086921A1/en not_active Abandoned
- 1991-07-11 WO PCT/US1991/004913 patent/WO1992001467A1/en not_active Application Discontinuation
- 1991-07-11 JP JP91513333A patent/JPH05508159A/ja active Pending
- 1991-07-11 EP EP19910914013 patent/EP0539506A4/en not_active Withdrawn
- 1991-07-11 AU AU83056/91A patent/AU8305691A/en not_active Abandoned
- 1991-07-17 IE IE249891A patent/IE912498A1/en unknown
- 1991-07-18 PT PT98373A patent/PT98373A/pt not_active Application Discontinuation
- 1991-07-18 ZA ZA915639A patent/ZA915639B/xx unknown
1993
- 1993-01-12 FI FI930123A patent/FI930123A0/fi not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO1992001467A1 (en)	1992-02-06
EP0539506A4 (en)	1993-11-24
PT98373A (pt)	1992-06-30
EP0539506A1 (en)	1993-05-05
IE912498A1 (en)	1992-01-29
CA2086921A1 (en)	1992-01-19
AU8305691A (en)	1992-02-18
FI930123A (fi)	1993-01-12
ZA915639B (en)	1992-04-29
FI930123A0 (fi)	1993-01-12

Publication	Publication Date	Title
Go et al.	2019	Extracellular Vesicle–Mimetic Ghost Nanovesicles for Delivering Anti‐Inflammatory Drugs to Mitigate Gram‐Negative Bacterial Outer Membrane Vesicle–Induced Systemic Inflammatory Response Syndrome
US5192264A (en)	1993-03-09	Methods and apparatus for treating disease states using oxidized lipoproteins
JP2825804B2 (ja)	1998-11-18	抗原を導入したリポソーム
Manjunath et al.	2021	Recent case studies on the use of ozone to combat coronavirus: Problems and perspectives
Hoffman et al.	1987	Augmentation of rat alveolar macrophage migration by surfactant protein
Bocci et al.	2009	Mechanisms of action and chemical-biological interactions between ozone and body compartments: a critical appraisal of the different administration routes
JP2018515567A (ja)	2018-06-14	組合せｈｉｖ治療薬
Berard et al.	1992	Effect of low doses of L-carnitine on the response to recombinant human erythropoietin in hemodialyzed children: about two cases
US5366440A (en)	1994-11-22	Methods for treating disease states using oxidized lipoproteins in conjunction with chemotherapeutic effector agents
MROCZEK et al.	1976	Diazoxide therapy: use and risks
JPH05508159A (ja)	1993-11-18	酸化リポプロテインを使用するウイルス感染症の治療方法
US5217716A (en)	1993-06-08	Method for treating viral infections using oxidized lipoproteins
US6303152B1 (en)	2001-10-16	Process for the production of substances that have been bactericidally treated and/or exhibit immune-modulatory activity, and the use thereof
JPH05501258A (ja)	1993-03-11	オキシダイズされたリポプロテインを使用した病状治療法及び装置
JPH06504429A (ja)	1994-05-26	ウイルス複製の阻害
Conradi et al.	1983	Fatality due to paraquat intoxication: confirmation by postmortem tissue analysis
JPS63188391A (ja)	1988-08-03	細菌破壊に及び／又は免疫調節に有効な物質の製造方法並びにこれを使用する方法
WO2018177140A1 (zh)	2018-10-04	脂质体用于治疗慢性乙型病毒性肝炎的用途
JOBLING et al.	1915	The therapeutic action of iodin
RU2275921C2 (ru)	2006-05-10	Способ лечения хронических диффузных заболеваний печени применением курса внутривенных инфузий растворов гипохлорита натрия
Tarro	2020	Different background of immunological response according to previous zoonotic experience with coronavirus
Rakovsky et al.	2009	Application of ozone in medicine
SINKOVICS et al.	1976	Hairy cells in long-term cultures
RU2248796C2 (ru)	2005-03-27	Фармацевтическая композиция (варианты), не содержащая белков и пептидов, для нейтрализации и/или удаления эндотоксинов из организма
JPH0124134B2 (fi)	1989-05-10